Document:

Exhibit
10.1 

 

FORM
OF

AGREEMENT
TO EXHANGE WARRANTS 

 

Ritter
Pharmaceuticals, Inc.

1880
Century Park East, Suite 1000

Los
Angeles, California 90067

Ladies
and Gentlemen:

 

This
is to record the agreement between Ritter Pharmaceuticals, Inc. (the “Company”) and _________ (the “Warrantholder”)
regarding the terms on which the Company will issue shares of common stock (“Common Stock”), par value $0.001 per
share, to the Warrantholder in exchange for warrants originally issued to the Warrantholder on October 30, 2018 (the “2018
Warrants”) entitling the holders to purchase shares of Common Stock, which Agreement is as follows:

 

	 	1.	The
    Company hereby agrees to issue __________ shares (the “Exchange Shares”) of Common Stock to the Warrantholder
    in exchange for __________ 2018 Warrants (the “Exchange”). 
	 	 	 
	 	2.	In
    order to carry out the exchange of the Exchange Shares for the 2018 Warrants described in Section 1, at or prior to 6:00 p.m.,
    Eastern Time on February 24, 2020 (the “Exchange Date”) (a) the number of Warrants stated in Section 1 shall be
    automatically deemed cancelled upon receipt of the Exchange Shares, and (b) the Company will cause Corporate Stock Transfer,
    Inc., as transfer agent for the Company, to issue via the Deposit / Withdrawal at Custodian system into an account with The
    Depositary Trust Company (“DTC”) specified by the Warrantholder, the number of shares of Common Stock stated in
    Section 1. The Exchange Shares shall not bear any restrictive legends. No later than five Nasdaq Capital Market trading days
    following the date hereof, the Warrantholder shall deliver the original certificate representing the 2018 Warrants stated
    in Section 1 above to the Company for cancellation. However, failure to deliver the original certificate will not affect the
    automatic cancellation of the Warrants described in clause (a). If the Company fails for any reason to deliver the Exchange
    Shares without restriction or any restrictive legend by February 24, 2020, the Company shall pay to the Warrantholder, in
    cash, as liquidated damages and not as a penalty, for each $1,000 of Exchange Shares (based on the VWAP of the Common Stock
    on February 24, 2020) $10 per Nasdaq Capital Market trading day for each trading day after February 24, 2020 until the Exchange
    Shares without restriction or any restrictive legend are delivered to the Warrantholder. For purposes herein, “VWAP”
    means, for any date, if the Common Stock is then listed on the Nasdaq Capital Market or another trading market, the daily
    volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Nasdaq Capital Market
    or such trading market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m.
    (New York City time)).

 

	 	3.	The
    Warrantholder represents and warrants to the Company that:

 

	 	a.	The
    Warrantholder owns all the 2018 Warrants described in Section 1 and has all power and authority that is necessary to enable
    the Warrantholder to exchange them for Common Stock as contemplated by this Agreement, without requiring consent of any other
    person or any governmental authority. 
	 	 	 
	 	b.	After
    the 2018 Warrants described in Section 1 are automatically cancelled as described in Section 2, neither the Warrantholder
    nor any other person will have any rights under or with regard to the 2018 Warrants. 

 

    	1

    	 

    

 

	 	c.	The
    Warrantholder is aware that: 

 

i.
On February 4, 2020, the Company filed a registration statement on Form S-4 (the “Registration Statement”) relating
to a proposed merger (the “Merger”) with Qualigen, Inc. (“Qualigen”). Consummation of the Merger is subject
to certain closing conditions including, among other things, the Registration Statement being declared effective by the Securities
and Exchange Commission, approval by the stockholders of the Company and Qualigen, the Common Stock to be issued in the Merger
being approved for listing on Nasdaq, the consummation of a pre-closing Qualigen financing, and the Company’s stockholders’
equity being no less than $0.00 as of immediately prior to the effective time of the Merger.

 

ii.
Subject to the approval of the Company’s stockholders, as described in the Registration Statement, the Company intends to
effect a reverse stock split prior to the consummation of the Merger, at a ratio to be determined in the future. If there is a
reverse stock split, the number of shares that may be purchased by exercising the 2018 Warrants or the 2017 Warrants will be reduced
proportionately, and the exercise price of the 2018 Warrants and the 2017 Warrants will be increased proportionately.

 

iii.
The 2018 Warrants include a provision that states that upon a “Fundamental Transaction”,
which would include the Merger, a holder of 2018 Warrants will have the right to require the Company or any successor entity to
repurchase the 2018 Warrants at their fair value using the Black Scholes option pricing
formula described in the 2018 Warrant agreement.

 

iv.
The last sale price of the Common Stock reported on the Nasdaq Capital Market on February 20, 2020 was $0.2070 per share. The
Company is not aware of any trading in the 2018 Warrants.

 

v.
The Company files annual, quarterly and current reports and other information with the SEC. The materials the Company files with
the SEC are available on the SEC’s website, www.sec.gov. They also are available on the Company’s website,
www.ritterpharmaceuticals.com. The Company is current in its annual, quarterly and current reports and other filings with the
SEC for purposes of SEC Rule 144.

 

	 	4.	The
    Company represents and warrants to the Warrantholder as follows:

 

	 	a.	The Company has all power and authority, and has obtained all approvals, that are necessary to enable it to issue Common Stock in exchange for 2018 Warrants as contemplated by this Agreement.
	 	 	 
	 	b.	When the Company issues the Exchange Shares, those shares (i) will be issued in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) contained in Section 3(a)(9) of the Securities Act, and (ii) will be duly authorized and issued, fully paid and non-assessable and will be eligible for trading on the Nasdaq Capital Market. For purposes of SEC Rule 144, the holding period of the Exchange Shares will include the holding period of the 2018 Warrants, which is more than six months, and the Company agrees not to take a position contrary to this sentence. The Company agrees to take all actions, including, without limitation, the issuance by its legal counsel of any necessary legal opinions, necessary to issue to the Exchange Shares without restriction or any restrictive legend without the need for any action by the Warrantholder.

 

    	2

    	 

    

 

	 	5.	From the date hereof until fifteen (15) days following the Exchange Date, neither the Company nor any subsidiary of the Company shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents. For purposes herein, “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
	 	 	 
	 	6.	The Company covenants and agrees that it has not entered into an agreement to exchange warrants with any other holder of 2018 Warrants (each, an “Other Warrantholder”) for any material amendments, modifications or exchanges to the terms of such 2018 Warrants (or settlement or exchange of such 2018 Warrants for other material consideration) (each a “More Favorable Agreement”), that is more favorable to such Other Warrantholder than those of the Warrantholder pursuant to this Agreement. From the date hereof until the earlier of (a) ninety (90) days following the Exchange Date or (b) the closing of the proposed merger between the Company and Qualigen, if the Company enters into a More Favorable Agreement with terms that are materially different from this Agreement (“material” shall be in the reasonable determination of the Warrantholder), then (i) the Company shall provide written notice thereof to the Warrantholder promptly following the occurrence thereof and (ii) the terms and conditions of this Agreement that shall be, without any further action by the Warrantholder or the Company, automatically and retroactively to the date hereof, amended and modified in an economically and legally equivalent manner such that the Warrantholder shall receive the benefit of such more favorable material terms and/or conditions (as the case may be) set forth in such More Favorable Agreement, provided that upon written notice to the Company within five business days of such Company’s written notice, the Warrantholder may elect not to accept the benefit of any such amended or modified material term or condition, in which event the material term or condition contained in this Agreement shall continue to apply to the Warrantholder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Warrantholder. The provisions of this paragraph shall apply similarly and equally to each More Favorable Agreement and shall be effective whether or not the Warrantholder holds Exchange Shares at such time. The Company will notify the Warrantholder any time it enters into any agreement with any Other Warrantholder relating to the 2018 Warrants and, at the request of the Warrantholder, provide the Warrantholder with such agreement for its review.

 

    	3

    	 

    

 

	 	7.	The Company shall, on or before 8:30 a.m., New York City time, on the Nasdaq Capital Market trading day immediately following the date hereof issue a Current Report on Form 8-K disclosing all material terms of the transactions contemplated hereby and attaching the form of this Agreement as an exhibit thereto (such Current Report on Form 8-K with all exhibits attached thereto, the “8-K Filing”). From and after the filing of the 8-K Filing, the Warrantholder shall not be in possession of any material, nonpublic information received from the Company or any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the 8-K Filing. The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, provide the Warrantholder with any material, nonpublic information regarding the Company from and after the filing of the 8-K Filing without the express written consent of the Warrantholder. To the extent that the Company delivers any material, non-public information to the Warrantholder without the Warrantholder’s express prior written consent, the Company hereby covenants and agrees that the Warrantholder shall not have any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents not to trade on the basis of, such material, non-public information. The Company shall not disclose the name of the Warrantholder in any filing, announcement, release or otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Warrantholder or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that the Warrantholder will rely on the foregoing representations in effecting transactions in securities of the Company.

 

	 	 	The Warrantholder is aware that the issuance of Exchange Shares in exchange for the 2018 Warrants, as described in this Agreement, has not been registered under the Securities Act and that the Exchange Shares are being issued in reliance on an exemption from the registration requirements of the Securities Act contained in Section 3(a)(9) of the Securities Act. 
	 	 	 
	 	8.	This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile or .pdf transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined pursuant to the internal law of the State of New York.

 

(Signatures
on following page)

 

    	 	4	 

    	 

    

 

Please
sign a copy of this Agreement which, when it is signed by the Company, will constitute a legally binding agreement between the
Warrantholder and the Company.

 

	 	Very
    truly yours,
	 	 	 
	 	[WARRANTHOLDER]

	 	 	                               
	Dated:
    February 20, 2020	By
    	
	 	Name:
    	 
	 	Title:
    	 

 

AGREED
TO:

 

RITTER
PHARMACEUTICALS, INC.

 

	By:
    		 
	Name:	Andrew
    J. Ritter	 
	Title:	Chief
    Executive Officer	 

 

    	 	5mlm-ex417_265.htm

Exhibit 4.17

 

DESCRIPTION OF THE COMPANY’S CAPITAL STOCK

 

The following summarizes the material terms of the capital stock of Martin Marietta Materials, Inc. (“Martin Marietta”).  Martin Marietta is a corporation incorporated under the laws of the State of North Carolina, and accordingly its internal corporate affairs are governed by North Carolina law and by its Restated Articles of Incorporation, as amended (the “Charter”), and its Bylaws, as amended (the “Bylaws”), which are filed as exhibits to Martin Marietta’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission and available at www.sec.gov.  The following summary is qualified in its entirety by reference to the applicable provisions of North Carolina law and the Charter and the Bylaws, which are subject to future amendment in accordance with the provisions thereof.  Martin Marietta common stock is the only class of securities of Martin Marietta registered under Section 12 of the Securities Exchange Act of 1934, as amended.

 

Authorized Capital Stock

 

Martin Marietta’s authorized capital stock consists of 100,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share, of which 100,000 have been designated Class A preferred stock and 200,000 have been designated Class B preferred stock. The number of shares of Martin Marietta common stock issued and outstanding as of a recent date is set forth on the cover page of the most recent Annual Report on Form 10-K filed by Martin Marietta with the Securities and Exchange Commission.  As of the same date, Martin Marietta had no issued and outstanding shares of preferred stock.

 

Common Stock

 

Each holder of a share of Martin Marietta common stock is entitled to one vote for each share held of record on the applicable record date on each matter voted on at a meeting of shareholders.  The holders of Martin Marietta common stock have no preemptive rights and no rights to convert their common stock into any other securities.  There are also no redemption or sinking fund provisions applicable to the Martin Marietta common stock.

 

Holders of Martin Marietta common stock are entitled to receive dividends as may be declared from time to time by Martin Marietta’s board of directors out of funds legally available therefor.  Holders of Martin Marietta common stock are entitled to share pro rata, upon any liquidation or dissolution of Martin Marietta, in all remaining assets available for distribution to shareholders after payment or providing for Martin Marietta’s liabilities and the liquidation preference of any outstanding preferred stock.  The rights, preferences and privileges of the holders of Martin Marietta common stock are subject to and may be adversely affected by the rights of holders of shares of Class A preferred stock and Class B preferred stock, and any other series of Martin Marietta’s preferred stock that Martin Marietta may designate and issue in the future.

 

 

Class A Preferred Stock and Class B Preferred Stock

 

Ranking.  If and when issued, each of Martin Marietta’s Class A preferred stock and Class B preferred stock would rank ahead of its common stock with respect to the payment of dividends and the distribution of assets in the event of Martin Marietta’s liquidation or dissolution.  Each of the Class A preferred stock and the Class B preferred stock would rank junior to all other series of Martin Marietta’s preferred stock as to the payment of dividends and the distribution of assets, unless the terms of any such series provide otherwise.

 

Dividends.  Subject to the prior and superior rights of any shares of any series of preferred stock ranking prior and superior to the shares of Class A preferred stock and Class B preferred stock with respect to dividends, any holders of shares of Class A preferred stock and Class B preferred stock would receive when, as and if declared by Martin Marietta’s board of directors quarterly dividends out of funds legally available for the purpose, which would accrue and be cumulative.  Dividends would be payable in an amount per one one-thousandth of a share equal to one times the aggregate per share amount of all cash and non-cash dividends declared on the common stock and on the first day of January, April, July and October in each year, commencing, with respect to Class A preferred stock and Class B preferred stock, on the first quarterly dividend payment date after the first issuance of a share or fraction of a share of that class of preferred stock.

 

So long as any dividends or distributions payable on Class A preferred stock or Class B preferred stock are in arrears, no shares may be repurchased and no dividends may be declared or paid with respect to shares ranking junior to Class A preferred stock or Class B preferred stock, including Martin Marietta common stock.

 

Voting Rights.  Holders of shares of each of Martin Marietta’s Class A preferred stock and Class B preferred stock would be entitled to vote as one voting class with the holders of Martin Marietta common stock on all matters submitted to a vote of Martin Marietta shareholders.  Each one-thousandth of a share of Class A preferred stock and Class B preferred stock would entitle the holder to one vote on all matters submitted to a vote of Martin Marietta shareholders. In the event that Martin Marietta at any time declares any dividend on common stock payable in shares of common stock, subdivides the outstanding common stock or combines the outstanding common stock into a smaller number of shares, the number of votes per share to which holders of shares of Class A preferred stock and Class B preferred stock would be entitled to immediately prior to such event shall be adjusted by multiplying such number by a fraction the numerator of which is the shares of common stock outstanding immediately after such event and the denominator of which is the number of shares of common stock that would be outstanding immediately prior to such event.

 

If at any time dividends on any Class A preferred stock or Class B preferred stock are in arrears in an amount equal to four quarterly dividends, all holders of preferred stock with 

dividends in arrears in an amount equal to four quarterly dividends, voting as a class, will have the right to elect two directors. Except as set forth in the articles of amendment with respect to the Class A preferred stock and the Class B preferred stock, holders of Class A preferred stock or Class B preferred stock shall have no special voting rights with respect to such shares and their consent shall not be required (except to the extent they are entitled to vote with holders of common stock as set forth herein) for taking any corporate action.

 

If an alteration, amendment or repeal of any provision of the Charter would materially alter or change any of the powers, preferences or special rights of the Class A preferred stock or the Class B preferred stock, the affirmative vote of the holders of a majority of the outstanding shares of each such class of preferred stock so affected, voting separately as a class, would be required.

 

Rights upon Liquidation, Dissolution or Winding Up.  In the event of any voluntary or involuntary liquidation, dissolution or winding up of Martin Marietta, holders of Class A preferred stock and Class B preferred stock would be entitled to receive, before any distribution is made to the holders of common stock or any other series of stock ranking junior to such class of preferred stock, a liquidation preference in the amount of $10.00 per share (which is equal to $0.01 per one one-thousandth of a share), plus an amount equal to accrued and unpaid dividends and distributions.  Thereafter, the holders of Class A preferred stock and Class B preferred stock would be entitled to receive an aggregate amount per one one-thousandth of a share equal to one times the aggregate amount to be distributed per share to holders of shares of common stock.  Following the payment of the foregoing, the holders of Class A preferred stock and Class B preferred stock and holders of shares of common stock shall receive their ratable and proportionate share of the remaining assets to be distributed.  In the event that there are not sufficient assets to permit payment in full of the Class A preferred stock and the Class B preferred stock liquidation preference and the liquidation preferences of all other series of preferred stock, if any, which rank on parity with the Class A preferred stock and the Class B preferred stock, then such remaining assets would be distributed ratably to the holders of such parity shares in proportion to their respective liquidation preference.

 

Redemption.  Shares of Class A preferred stock and Class B preferred stock are not redeemable.

 

Additional Classes or Series of Preferred Stock

 

The Charter permits Martin Marietta’s board of directors, without further action by the shareholders, to issue one or more additional series of preferred stock with such designations, preferences, limitations and relative rights as the board of directors may determine from time to time.  Accordingly, without action by the shareholders, Martin Marietta’s board of directors may designate and authorize the issuance of additional classes or series of preferred stock having voting rights, dividend rights, conversion rights, redemption provisions (including sinking fund provisions) and rights in liquidation, dissolution or winding up that are superior to those of Martin Marietta’s common stock.

 

Charter and Bylaw Provisions; Takeover Statutes

 

A number of provisions in the Charter, the Bylaws and the North Carolina Business Corporations Act (the “NCBCA”) may make it more difficult to acquire control of Martin Marietta or remove its management.

 

Removal of Directors.  Directors may be removed only for cause by a majority vote of the shareholders.  Cause for removal is deemed to exist only if the director has been convicted in a court of competent jurisdiction of a felony or has been adjudged by a court of competent jurisdiction to be liable for fraudulent or dishonest conduct, or gross abuse of authority or discretion, with respect to Martin Marietta, and such conviction or adjudication has become final and non-appealable. If a director is elected by a voting group of Martin Marietta shareholders, only such shareholders may participate in the vote to remove such director.

 

Approval of Certain Share Repurchases, Mergers, Consolidations, Sales and Leases.  The Charter requires any purchase by Martin Marietta of shares of its voting stock from an interested shareholder (as defined below) who has beneficially owned such securities for less than two years prior to the date of such purchase or any agreement to purchase, other than pursuant to an offer to all shareholders of the same class of shares, at a per share price in excess of the market price, be approved by the affirmative vote of the holders of a majority of Martin Marietta’s voting stock not beneficially owned by the interested shareholder, voting together as a single class.

 

In addition, the Charter requires Martin Marietta to get the approval of not less than 66-2/3% of its voting stock not beneficially owned by an interested shareholder and 80% of all of its voting stock, in addition to any vote required by law, before Martin Marietta may enter into various transactions with interested shareholders, including the following:

 

	
 
	
•
	
any merger or consolidation of Martin Marietta or any of its subsidiaries with (i) any interested shareholder or (ii) any other corporation (whether or not itself an interested shareholder) which is, or after such merger or consolidation would be, an affiliate of an interested shareholder;

 

	
 
	
•
	
any sale, lease, exchange, mortgage, pledge, transfer, or other disposition to or with any interested shareholder or any affiliate of any interested shareholder of any of Martin Marietta’s assets or any of its subsidiaries having an aggregate fair market value of $10,000,000 or more;

 

	
 
	
•
	
the issuance or transfer by Martin Marietta or any of its subsidiaries of any of Martin Marietta’s equity securities (including any security convertible into equity securities) or any of its subsidiaries having an aggregate fair market value of $10,000,000 or more to any interested shareholder or any affiliate of any interested shareholder in exchange for cash, securities, and/or other property;

 

	
 
	
•
	
the adoption of any plan or proposal for the liquidation or dissolution of Martin Marietta proposed by or on behalf of an interested shareholder or any affiliate of any interested shareholder; or

 

	
 
	
•
	
any reclassification of securities or recapitalization of Martin Marietta, or any merger or consolidation of Martin Marietta with any of its subsidiaries, or any other transaction (whether or not involving an interested shareholder) which has the effect, directly or indirectly, of increasing the proportionate share of the outstanding shares of any class of equity (including any securities convertible into equity securities) securities of Martin Marietta or any of its subsidiaries that are directly or indirectly owned by any interested shareholder or any affiliate of any interested shareholder.

 

However, no such vote is required for any transaction approved by a majority of Martin Marietta’s disinterested directors or for the purchase by Martin Marietta of shares of voting stock from an interested shareholder unless such vote is required by the provision described in the first paragraph of this subsection.

 

The Charter defines an interested shareholder as any individual, firm, corporation, partnership, or other entity who or that:

 

	
 
	
•
	
is the beneficial owner, directly or indirectly, of five percent or more of Martin Marietta’s outstanding voting stock;

 

	
 
	
•
	
is an affiliate of Martin Marietta and at any time within the two-year period immediately prior to the date as of which a determination is being made was the beneficial owner, directly or indirectly, of five percent or more of Martin Marietta’s outstanding voting stock; or

 

	
 
	
•
	
is an assignee of or successor to any shares of Martin Marietta’s voting stock that were at any time within the immediately prior two-year period beneficially owned by any person described in above if such assignment or succession occurred in the course of one or more transactions not involving a public offering.

 

Advance Notice of Proposals and Nominations. The Bylaws provide that shareholders must provide timely written notice to bring business before an annual meeting of shareholders or to nominate candidates for election as directors at an annual meeting of shareholders.  Generally, to be timely, notice for an annual meeting must be received at Martin Marietta’s principal office not less than 60 days nor more than 90 days prior to the first anniversary of the mailing of the preceding year’s proxy statement in connection with the annual meeting of Martin Marietta shareholders. The Bylaws also specify the form and content of a shareholder’s notice.  These provisions may prevent shareholders from bringing matters before an annual meeting of shareholders or from nominating candidates for election as directors at an annual meeting of shareholders.

 

Limits on Special Meetings.  A special meeting of the shareholders of Martin Marietta may be called only by the chairman of its board of directors, its president, or by its board of directors or executive committee.

 

Takeover Statutes. The NCBCA includes two takeover-related statutes: the Shareholder Protection Act and the Control Share Acquisition Act.  The Shareholder Protection Act restricts business combination transactions involving a North Carolina public corporation and a beneficial owner of 20 percent or more of its voting stock.  The Control Share Acquisition Act precludes an acquirer of the shares of a North Carolina public corporation who crosses one of three voting thresholds, 20 percent, 33-1/3 percent or 50 percent, from obtaining voting control of the shares unless a majority in interest of the disinterested shareholders of the corporation votes to grant voting power to the shares. Neither of these statutes applies to Martin Marietta because, as permitted by these statutes, Martin Marietta elected not to be covered by them and included a provision in its initial articles of incorporation reflecting that election.

 

Transfer Agent

 

The transfer agent and registrar for Martin Marietta’s common stock is the American Stock Transfer & Trust Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]